Table 3.
Adverse events beyond 30 days after TAVI, AVR and medical treatment
| TAVIa | AVRa | Medicala | |||
|---|---|---|---|---|---|
| All (n = 106) | Fatal (n = 40) | All (n = 10) | Fatal (n = 5) | Fatal (n = 59) | |
| Cardiac | 46 (43) | 19 (48) | 5 (50) | 1 (20) | 31 (53) |
| Heart failure | 13 (12) | 4 (10) | 4 (40) | 1 (20) | 19 (32) |
| Sudden death | 8 (8) | 8 (20) | 0 | 0 | 9 (15) |
| Myocardial infarction | 2 (2) | 2 (5) | 1 (20) | 0 | 1 (2) |
| Cardiac re-intervention | 3 (3)1 | 0 | 0 | 0 | 0 |
| Stroke or TIA | 11 (10)2 | 4 (10) | 0 | 0 | 2 (3) |
| Pacemaker implantation | 9 (9) | 1 (3)3 | 0 | 0 | 0 |
| Non-cardiac | 56 (53) | 21 (52) | 5 (50) | 4 (80) | 9 (15) |
| Infection | 17 (16) | 8 (20) | 1 (10) | 1 (20) | 5 (8) |
| Renal failure | 7 (7) | 4 (10) | 2 (20) | 2 (40) | 0 |
| Vascular | 3 (3) | 0 | 0 | 0 | 0 |
| Bleeding (non-cranial) | 3 (3) | 1 (3) | 1 (10) | 0 | 0 |
| Neoplasm | 9 (8) | 4 (10) | 0 | 0 | 1 (2) |
| Metabolic disease | 2 (2) | 2 (5) | 0 | 0 | 0 |
| Other | 15 (14) | 2 (5)4 | 1 (10) | 1 (20)5 | 3 (5)6 |
| Unknown | 4 (4) | 0 | 0 | 0 | 19 (32) |
aMedian follow-up was 298 (IQR: 107–688) days in the TAVI group, 836 (IQR: 327–1269) days in the AVR group and 456 (IQR: 187–869) days in the medical group
1Re-interventions before discharge included AVR (n = 1) and post-implantation balloon aortic valvuloplasty (n = 2)
2Including TIA (n = 4); of the 11 events, 9 were ischaemic of which 2 fatal and 2 were haemorrhagic, both of which fatal
3Pneumothorax following pacemaker implantation (n = 1)
4Blood transfusion reaction (n = 1), euthanasia (n = 1)
5Delirium (n = 1)
6Obstructive pulmonary disease (n = 2), lung emboli (n = 1)